Overview
- Consolidated profit after tax rose to Rs 1,437 crore and revenue reached Rs 8,805 crore for the quarter ended September 30.
- Momentum in branded markets and steady Nicotine Replacement Therapy contributions helped offset lower US lenalidomide sales.
- North America generics revenue declined 13% to Rs 3,241 crore due to price erosion and reduced lenalidomide volumes.
- Europe revenue increased to Rs 1,376 crore, India grew 13% to Rs 1,578 crore, emerging markets rose 14% to Rs 1,655 crore, and PSAI advanced 12% to Rs 945 crore.
- The stock closed 0.32% higher at Rs 1,284 on the BSE, and Sanjay Sharma was named CHRO effective December 1 following Archana Bhaskar's November 30 exit.